Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vilazodone for the Treatment of Posttraumatic Stress Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Southern California Institute for Research and Education
Forest Laboratories
Information provided by (Responsible Party):
Michael Hollifield, MD, Southern California Institute for Research and Education Identifier:
First received: October 18, 2012
Last updated: November 17, 2014
Last verified: November 2014

The purpose of this study is to determine whether vilazodone is effective in the treatmen of Posttraumatic Stress Disorder (PTSD)and co-morbid mild or more depression.

Condition Intervention Phase
Drug: Treatment (Viibryd)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder

Resource links provided by NLM:

Further study details as provided by Southern California Institute for Research and Education:

Primary Outcome Measures:
  • PTSD symptoms [ Time Frame: four months ] [ Designated as safety issue: No ]
  • PTSD Diagnosis [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Depression [ Time Frame: four months ] [ Designated as safety issue: No ]
  • Sleep [ Time Frame: 4 months ] [ Designated as safety issue: No ]
  • Anxiety [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Biomarkers [ Time Frame: four months ] [ Designated as safety issue: No ]

Estimated Enrollment: 64
Study Start Date: October 2012
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (Viibryd)
10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
Drug: Treatment (Viibryd)
Other Name: Vilazodone
Placebo Comparator: Placebo
will be compared to the treatment group (viibryd)


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must satisfy DSM-IV diagnostic criteria for chronic PTSD
  • Evidence of PTSD disease base upon one or more of the following:
  • Mild or greater depression on the Beck Depression Inventory -II (BDI-II, score> 12).
  • May have other symptom co-morbid with PTSD (e.g., anxiety or somatic pain)
  • Ability to comprehend and satisfactorily comply with protocol required and signed written informed consent prior to entering study procedure
  • May be in psychotherapy if initiated at least three months prior to the screening visit. Subject must not discontinue or otherwise alter therapy during the study.
  • Subject may not have taken any psychopharmacological medications within 7 days prior to Baseline visit.
  • Negative urine pregnancy test at screening visit and for the duration of the study for women of childbearing potential.

Exclusion Criteria:

  • Patients with a concurrent DSM-IV Axis I diagnosis in any of the following categories:

    1. Delirium, Dementia, Amnestic and other Cognitive disorders
    2. Lifetime Schizophrenia and other Psychotic Disorders
    3. lifetime Bipolar I Disorder
    4. Bipolar-II Disorder with an episode of hypomania within the last year
    5. Alcohol or Substance Dependence or Abuse (excluding nicotine) in one month prior to the Screening Visit
    6. Any other concurrent Axis I Disorder (including Major Depressive Disorder) must be secondary to the primary diagnosis of PTSD.
  • Decisional incapacity (dementia)
  • Use of centrally acting medications that potentially have an effect on biological expression
  • Chronic pain levels requiring use of any opiate medications
  • Known exposure to chemicals of physical traumas that cause neuropsychiatric sequelae
  • Past chronic PTSD
  • History of 2 or more treatment failures on SSRIs given primarily for the treatment of PTSD, in adequate does at the Investigator's opinion, for at least 8 weeks
  • History of intolerance or hypersensitivity to SSRI's
  • History of seizures
  • Significant risk of committing suicide, or are homicidal or violent and in the Investigator's opinion in significant imminent risk of hurting others
  • Treated with depot-neuroleptic within 3 months or MAO inhibitors within 30 day prior to Baseline visit
  • Received ECT within 3 months prior to Screening visit
  • Pregnant or nursing, women of childbearing potential who are sexually active and do not use adequate contraception, or who are judged to be unreliable in their use of contraception
  • Positive urine drug screen, unless proven to be prescribed for a short-term course of treatment. Drug screen must be repeated at least 7 days after the last dose of prescription medication containing narcotics
  • A medical condition, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial
  • Requiring concomitant treatment with any psychotropic drug (except zolpidem for sleep)
  • Plans to initiate or terminate any form of psychotherapy or behavior therapy during the study
  • Receiving disability payments (> 50 % service connections or total Social Security) or who are involved in litigation for PTSD or other psychiatric illnesses.
  • Unable to speak, read, and understand English or are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01715519

Contact: Linda Theresa X Nguyen, MPH 562-826-8000 ext 7212

United States, California
Veterans Affairs Long Beach Healthcare System Recruiting
Long Beach, California, United States, 90822
Contact: Linda Theresa X Nguyen, MPH    562-826-8000 ext 7212   
Principal Investigator: Michael A Hollifield, MD         
United States, Nebraska
Veterans Affairs Nebraska Western-Iowa Healthcare Systems Recruiting
Omaha, Nebraska, United States, 68105
Contact: Kim Carroll    402-995-4959   
Principal Investigator: Sriram Ramaswamy, MD         
Sponsors and Collaborators
Southern California Institute for Research and Education
Forest Laboratories
  More Information

No publications provided

Responsible Party: Michael Hollifield, MD, Director of Program for Traumatic Stress, Southern California Institute for Research and Education Identifier: NCT01715519     History of Changes
Other Study ID Numbers: VII-IT-05
Study First Received: October 18, 2012
Last Updated: November 17, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Southern California Institute for Research and Education:

Additional relevant MeSH terms:
Depressive Disorder
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Behavioral Symptoms
Mental Disorders
Mood Disorders processed this record on November 23, 2014